WallStSmart

Hims Hers Health Inc (HIMS)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 2675% more annual revenue ($65.77B vs $2.37B). MRK leads profitability with a 13.6% profit margin vs -0.0%. HIMS appears more attractively valued with a PEG of 2.16. MRK earns a higher WallStSmart Score of 50/100 (D+).

HIMS

Avoid

29

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 3.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.61

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HIMSSignificantly Overvalued (-29.1%)

Margin of Safety

-29.1%

Fair Value

$25.32

Current Price

$28.09

$2.77 premium

UndervaluedFair: $25.32Overvalued
MRKSignificantly Overvalued (-60.9%)

Margin of Safety

-60.9%

Fair Value

$81.10

Current Price

$131.07

$49.97 premium

UndervaluedFair: $81.10Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HIMS0 strengths · Avg: 0/10

No standout strengths identified

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$307.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

HIMS4 concerns · Avg: 4.0/10
PEG RatioValuation
2.164/10

Expensive relative to growth rate

Price/BookValuation
14.6x4/10

Trading at 14.6x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

Altman Z-ScoreHealth
1.614/10

Distress zone — elevated risk

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : HIMS

HIMS has a balanced fundamental profile.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : HIMS

The primary concerns for HIMS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.54 is elevated, increasing financial risk.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

HIMS profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

HIMS carries more volatility with a beta of 2.34 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hims Hers Health Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?